Literature DB >> 7749974

Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists.

T J Witek1, D A Canestrari, R D Miller, J Y Yang, D K Riker.   

Abstract

BACKGROUND: While first generation H1-receptor antagonists are widely used, there are relatively few data describing their comparative effects on subjective daytime sleepiness and psychomotor performance.
OBJECTIVE: To compare the effects of first generation H1 receptor antagonists on subjective daytime sleepiness and psychomotor performance.
METHODS: We conducted two single-dose, cross-over studies. In the first, we validated our methodology in 18 healthy subjects by examining the response to diphenhydramine (50 mg), terfenadine (60 mg), and placebo. In the second trial, we evaluated the relative effects following diphenhydramine (50 mg), diphenhydramine (25 mg), chlorpheniramine (4 mg), and placebo. Psychomotor tests included choice reaction time, hand steadiness, and a test that divided attention between tracking and reaction time. Introspective drowsiness was measured using a visual analog scale and the Stanford Sleepiness Scale. Assessments were made prior to dosing and at one, three, and five hours after dosing; a 7-hour post-drug assessment was included in the second trial.
RESULTS: In the first trial, 50 mg diphenhydramine produced significant impairment relative to placebo in both subjective and objective assessments (P < .05). Responses following terfenadine did not differ from placebo. In the second study, all three regimens produced subjective and objective soporific effects to a significantly greater degree than placebo. For example, significant introspective sleepiness was noted three hours following all three regimens (P < .05) and slower choice reaction times were noted one and three hours after dosing (P < .05). The general rank order of effects was diphenhydramine (50 mg), followed by diphenhydramine (25 mg), followed by chlorpheniramine (4 mg). Significant differences among the three regimens were, for the most part, confined to greater soporific effects from diphenhydramine relative to chlorpheniramine (P < .05).
CONCLUSIONS: Taken together, our observations confirm that subjective and objective measures of sleepiness and psychomotor performance occur following single doses of diphenhydramine and chlorpheniramine, but not terfenadine. Differences in soporific effects do exist among regimens of first-generation compounds.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7749974

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  10 in total

1.  Event-related potentials reflect impaired temporal interval learning following haloperidol administration.

Authors:  Sarah E Forster; Patrick Zirnheld; Anantha Shekhar; Stuart R Steinhauer; Brian F O'Donnell; William P Hetrick
Journal:  Psychopharmacology (Berl)       Date:  2017-06-10       Impact factor: 4.530

2.  Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia.

Authors:  Antony D Loebel; Cynthia O Siu; Josephine B Cucchiaro; Andrei A Pikalov; Philip D Harvey
Journal:  CNS Spectr       Date:  2013-12-13       Impact factor: 3.790

3.  Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine.

Authors:  N Okamura; K Yanai; M Higuchi; J Sakai; R Iwata; T Ido; H Sasaki; T Watanabe; M Itoh
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

4.  Sleep in the Elderly: Burden, Diagnosis, and Treatment.

Authors:  W Vaughn McCall
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

5.  Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers.

Authors:  J M Gandon; H Allain
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

6.  The effect of IM droperidol on driving performance.

Authors:  Jessica Fulton; Gary Popovetsky; Jeanne L Jacoby; Michael B Heller; James Reed
Journal:  J Med Toxicol       Date:  2006-09

7.  Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis.

Authors:  Patrick W Sullivan; Sheryl L Follin; Michael B Nichol
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 8.  Safety of antihistamines in children.

Authors:  A P Ten Eick; J L Blumer; M D Reed
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

9.  Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia.

Authors:  Philip D Harvey; Cynthia O Siu; Antony D Loebel
Journal:  Schizophr Res Cogn       Date:  2016-06-02

10.  The effects of meclizine on motion sickness revisited.

Authors:  Tobias Wibble; Johanna Engström; Luca Verrecchia; Tony Pansell
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.